Maharashtra Herald

Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics

 Breaking News
  • No posts were found

Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics

September 30
14:50 2022
Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics
The Retinal Vein Occlusion market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Vein Occlusion pipeline products will significantly revolutionize the Retinal Vein Occlusion market dynamics.

DelveInsight’sRetinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Retinal Vein Occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Retinal Vein Occlusion Overview

Retinal vein occlusion (RVO), second most common retinal vascular disorder after diabetic retinopathy, is an obstruction of the retinal venous system by thrombus formation and may involve the central, hemi-central, or branch retinal vein. The most common etiological factor is compression by adjacent atherosclerotic retinal arteries. Other possible causes are external compression or disease of the vein wall, e.g., vasculitis.

 

Some of the key facts of the Retinal Vein Occlusion Market Report:  

  • The Retinal Vein Occlusion market size was valued at USD 2,378.1 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • In the year 2021, the total prevalent cases of Retinal Vein Occlusion were approximately 2,708,118 cases in the 7MM, which are expected to increase by 2032 
  • Among EU-5 countries, the highest number of prevalent cases of Retinal Vein Occlusion were in Germany (approximately 225,397 cases) in the year 2021, which are expected to increase by 2032 
  • In 2021, the total diagnosed prevalent cases of Retinal Vein Occlusion in the 7MM were approximately 1,518,208 cases, which are estimated to increase by 2032 
  • Key Retinal Vein Occlusion Companies: Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others 
  • Key Retinal Vein Occlusion Therapies: TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others 
  • The Retinal Vein Occlusion epidemiology based on type-specific distribution analyzed that the type-specific distribution of Retinal Vein Occlusion suggests a higher prevalence of BRVO than CRVO 

 

Get a Free sample for the Retinal Vein Occlusion Market Report 

 

Key benefits of the Retinal Vein Occlusion Market report:

  1. Retinal Vein Occlusion market report covers a descriptive overview and comprehensive insight of the Retinal Vein Occlusion Epidemiology and Retinal Vein Occlusion market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Retinal Vein Occlusion market report provides insights on the current and emerging therapies.
  3. Retinal Vein Occlusion market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Retinal Vein Occlusion market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Retinal Vein Occlusion market.

 

Discover more about therapies set to grab major Retinal Vein Occlusion market share @ Retinal Vein Occlusion market forecast 

 

Retinal Vein Occlusion Epidemiology Segmentation:

The Retinal Vein Occlusion market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Retinal Vein Occlusion
  • Prevalent Cases of Retinal Vein Occlusion by severity
  • Gender-specific Prevalence of Retinal Vein Occlusion
  • Diagnosed Cases of Episodic and Chronic Retinal Vein Occlusion 

 

Retinal Vein Occlusion Market  

The dynamics of the Retinal Vein Occlusion market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as AR-1105, GB-102, ONS-5010, and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Retinal Vein Occlusion epidemiology trends @ Retinal Vein Occlusion Epidemiological Insights 

 

Retinal Vein Occlusion Market Drivers

  • Rich Retinal Vein Occlusion pipeline 
  • Advancement in drug Retinal Vein Occlusion therapies
  • Increase in knowledge and awareness 
  • Increasing prevalence of Retinal Vein Occlusion

 

Retinal Vein Occlusion Therapies and Key Companies

  • TLC399: Taiwan Liposome Company
  • AR-1105: Aerie Pharmaceuticals
  • GB-102: Graybug Vision
  • ONS-5010 (Lytenava): Outlook Therapeutics
  • KSI-301: Kodiak Sciences
  • Vabysmo (faricimab): Roche/ Chugai Pharmaceuticals

 

Scope of the Retinal Vein Occlusion Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Retinal Vein Occlusion Companies: Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others
  • Key Retinal Vein Occlusion Therapies: TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others
  • Retinal Vein Occlusion Therapeutic Assessment: Retinal Vein Occlusion current marketed and Retinal Vein Occlusion emerging therapies
  • Retinal Vein Occlusion Market Dynamics:  Retinal Vein Occlusion market drivers and Retinal Vein Occlusion market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Retinal Vein Occlusion Unmet Needs, KOL’s views, Analyst’s views, Retinal Vein Occlusion Market Access and Reimbursement 

 

Retinal Vein Occlusion Market Barriers

  • Cost Consciousness 
  • Risk and complications 
  • Lack of focus on for visual restoration 
  • Failure of investigational drugs 
  • Invasion of biosimilar in future

 

Table of Contents 

1. Retinal Vein Occlusion Market Report Introduction

2. Executive Summary for Retinal Vein Occlusion

3. SWOT analysis of Retinal Vein Occlusion

4. Retinal Vein Occlusion Patient Share (%) Overview at a Glance

5. Retinal Vein Occlusion Market Overview at a Glance

6. Retinal Vein Occlusion Disease Background and Overview

7. Retinal Vein Occlusion Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinal Vein Occlusion 

9. Retinal Vein Occlusion Current Treatment and Medical Practices

10. Retinal Vein Occlusion Unmet Needs

11. Retinal Vein Occlusion Emerging Therapies

12. Retinal Vein Occlusion Market Outlook

13. Country-Wise Retinal Vein Occlusion Market Analysis (2019–2032)

14. Retinal Vein Occlusion Market Access and Reimbursement of Therapies

15. Retinal Vein Occlusion Market Drivers

16. Retinal Vein Occlusion Market Barriers

17.  Retinal Vein Occlusion Appendix

18. Retinal Vein Occlusion Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Retinal Vein Occlusion treatment, visit @ Retinal Vein Occlusion Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories